Piper Sandler began coverage of Bio-Techne Corporation on June 11 with a Neutral rating and a $65 price target [1].
The move signals a cautious outlook on the life-sciences tools sector. Investors are monitoring the industry to identify the next significant catalyst for growth before committing to aggressive positions.
Bio-Techne, which trades on the NASDAQ under the ticker TECH, is now under the firm's active monitoring [1]. The Neutral rating suggests that the analyst expects the stock to perform in line with the broader market in the near term.
Piper Sandler said it is taking a wait-and-see approach for stocks within the tools sector [2]. The firm said it prefers patience until the industry establishes a clear trajectory for expansion [2]. This cautious stance reflects a broader uncertainty regarding which specific technologies or market shifts will drive the next wave of revenue for life-sciences providers.
While the firm has initiated coverage on Bio-Techne, it has identified other preferences within the sector. For instance, Twist Bioscience has been favored by Piper Sandler despite the general hesitation toward tools stocks [2].
The initiation of coverage on June 11 [1] comes as companies in the sector navigate a complex post-pandemic environment. Many firms are adjusting their valuations as the surge in research spending from previous years stabilizes.
“Piper Sandler initiated coverage of Bio-Techne with a Neutral rating and a $65 price target.”
The Neutral rating and the 'wait-and-see' approach suggest that while Bio-Techne remains a stable entity, the life-sciences tools industry lacks a definitive short-term catalyst. By favoring specific companies like Twist Bioscience over a general sector bullishness, Piper Sandler is signaling a transition toward selective, high-conviction investing rather than broad sector bets.
